Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain

Claudia Valenzuela, maria molina molina, Jose Antonio Rodriguez Portal, ana Romero Ortiz, Esteban Cano, maria jesus Rodriguez Nieto, Rosalia Laporta, Julio Ancochea
European Respiratory Journal 2017 50: PA4883; DOI: 10.1183/1393003.congress-2017.PA4883
Claudia Valenzuela
1Hospital Universitario de La princesa,IIS Princesa (IP), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
maria molina molina
2Hospital Universitario de Bellvitge, IDIBELL Hospitalet de Llobregat, Barcelona, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jose Antonio Rodriguez Portal
3Hospital Universitario Virgen del Rocío, sevilla, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ana Romero Ortiz
4Hospital Virgen de las Nieves, granada, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Esteban Cano
5Hospital Universitario Lucus Augusti, Lugo, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
maria jesus Rodriguez Nieto
6Fundación Jiménez Díaz, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rosalia Laporta
7Hospital Universitario Puerta de Hierro, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julio Ancochea
8Hospital Universitario de la Princesa, IIS Princesa (IP, Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Introduction:. We present our real life experience of 79 patients treated with nintedanib. Objectives: To evaluate the results of a cohort of IPF patients treated with Nintedanib in different hospitals in Spain.

Methods: The collected data were: clinical, radiological, pulmonary function test and side effects related to the treatment with Nintedanib

Results: 79 patients were included, male (74.6%). At diagnosis HRCT shows UIP pattern (34 %), POSIBLE UIP pattern (34%), combination with emphysema was observed in 24 patients (30%), 28 patients underwent a surgical lung biopsy ( 35%). Pulmonary function test baseline data were (mean ± SD) FVC 79.5 % predicted (±17.61); DLCO 44.82 % predicted (±14). 6MWT distance was 446 meters (±116), initial SpO2 95% (±2.6) and final SpO2 86%(±6,8) Most treatments were started between august 2011 and june 2016, 7 patients (35%) participated in INPULSIS trials and only 2 patients switched from pirfenidone. Only 14 patients interrupt treatment (17.9%), 8 due to side effects and 6 due to progression of IPF and death, there were dose reduction in 31 patients (39%) but 21 patients (26.9%) could be re titrated to full dose. Regarding side effects 42 (53%) patients had diarrhea, 12(15%) had nausea and 20 (25%) showed weight loss. 12 patients (15%) had elevated transaminases. Acute exacerbations were recorded in 7 patients (9%)and 6 died.

Conclusions: The results of the real life experience in these cohort of IPF patients appears consistent with the data published so far in the clinical trials. Further monitoring is required to establish the efficacy and safety in clinical practice

  • Copyright ©the authors 2017
Previous
Back to top
Vol 50 Issue suppl 61 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain
Claudia Valenzuela, maria molina molina, Jose Antonio Rodriguez Portal, ana Romero Ortiz, Esteban Cano, maria jesus Rodriguez Nieto, Rosalia Laporta, Julio Ancochea
European Respiratory Journal Sep 2017, 50 (suppl 61) PA4883; DOI: 10.1183/1393003.congress-2017.PA4883

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Clinical experience with Nintedanib for treatment of idiopathic pulmonary fibrosis (IPF) in Spain
Claudia Valenzuela, maria molina molina, Jose Antonio Rodriguez Portal, ana Romero Ortiz, Esteban Cano, maria jesus Rodriguez Nieto, Rosalia Laporta, Julio Ancochea
European Respiratory Journal Sep 2017, 50 (suppl 61) PA4883; DOI: 10.1183/1393003.congress-2017.PA4883
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Treatment with nintedanib in patients with pleuroparenchymal fibroelastosis
  • Role of MUC1 in idiopathic pulmonary fibrosis: mechanistic insights
  • The efficacy of anti-fibrotic agents for acute exacerbation of idiopathic pulmonary fibrosis
Show more Diffuse Parenchymal Lung Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society